Compartir
array:23 [ "pii" => "S0025775304746345" "issn" => "00257753" "doi" => "10.1016/S0025-7753(04)74634-5" "estado" => "S300" "fechaPublicacion" => "2004-10-01" "aid" => "74634" "copyright" => "Elsevier España, S.L.. Todos los derechos reservados" "copyrightAnyo" => "2004" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2004;123:657-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2853 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 2494 "PDF" => 353 ] ] "itemSiguiente" => array:18 [ "pii" => "S0025775304746357" "issn" => "00257753" "doi" => "10.1016/S0025-7753(04)74635-7" "estado" => "S300" "fechaPublicacion" => "2004-10-01" "aid" => "74635" "copyright" => "Elsevier España, S.L." "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "edi" "cita" => "Med Clin. 2004;123:659-60" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1357 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 1130 "PDF" => 220 ] ] "es" => array:7 [ "idiomaDefecto" => true "titulo" => "Nuevos horizontes en el tratamiento de la psoriasis" "tienePdf" => "es" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "659" "paginaFinal" => "660" ] ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carlos Ferrándiz" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Carlos" "apellidos" => "Ferrándiz" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775304746357?idApp=UINPBA00004N" "url" => "/00257753/0000012300000017/v1_201307291635/S0025775304746357/v1_201307291635/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0025775304746333" "issn" => "00257753" "doi" => "10.1016/S0025-7753(04)74633-3" "estado" => "S300" "fechaPublicacion" => "2004-10-01" "aid" => "74633" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2004;123:652-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2478 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 2165 "PDF" => 306 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Abstinencia puntual y continuada con el tratamiento farmacológico del tabaquismo en la práctica clínica" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "652" "paginaFinal" => "656" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Continuous and momentous tobacco assistance with pharmacologic therapy in clinical practice" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Barrueco Ferrero, Carlos Jiménez Ruiz, Luis Palomo Cobos, Miguel Torrecilla García, Pedro Romero Palacios, Juan Antonio Riesco Miranda" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "Barrueco Ferrero" ] 1 => array:2 [ "nombre" => "Carlos Jiménez" "apellidos" => "Ruiz" ] 2 => array:2 [ "nombre" => "Luis Palomo" "apellidos" => "Cobos" ] 3 => array:2 [ "nombre" => "Miguel Torrecilla" "apellidos" => "García" ] 4 => array:2 [ "nombre" => "Pedro Romero" "apellidos" => "Palacios" ] 5 => array:2 [ "nombre" => "Juan Antonio" "apellidos" => "Riesco Miranda" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775304746333?idApp=UINPBA00004N" "url" => "/00257753/0000012300000017/v1_201307291635/S0025775304746333/v1_201307291635/es/main.assets" ] "es" => array:14 [ "idiomaDefecto" => true "titulo" => "Tratamiento de la psoriasis extensa y refractaria con infliximab" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "657" "paginaFinal" => "658" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Laura Mahiques Santos, Teresa Martínez-Menchón, José Luis Sánchez Carazo, Vicente Oliver Martínez, Carlos Joaquín Soriano Navarro, José Miguel Fortea Baixauli" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Laura" "apellidos" => "Mahiques Santos" "email" => array:1 [ 0 => "laura_mahiques@aedv.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Teresa" "apellidos" => "Martínez-Menchón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "José Luis" "apellidos" => "Sánchez Carazo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Vicente" "apellidos" => "Oliver Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Carlos Joaquín" "apellidos" => "Soriano Navarro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 5 => array:3 [ "nombre" => "José Miguel" "apellidos" => "Fortea Baixauli" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología y Venereología. Hospital General Universitario. Valencia." "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Cardiología. Hospital General Universitario. Valencia. España." "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "*" "correspondencia" => "Correspondencia: Dra. L. Mahiques Santos. Servicio de Dermatología y Venereología. Hospital General Universitario. Avda. Tres Cruces, s/n. 46014 Valencia. España." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Treatment of severe refractory psoriasis with infliximab" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2003-12-29" "fechaAceptado" => "2004-04-20" "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec222428" "palabras" => array:3 [ 0 => "Psoriasis" 1 => "Citocinas" 2 => "Tratamiento inmunitario" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec222429" "palabras" => array:3 [ 0 => "Psoriasis" 1 => "Cytokines" 2 => "Immune therapy" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Fundamento y objetivo</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El objetivo de este estudio fue determinar el número y la proporción de pacientes con psoriasis extensa y refractaria que mejoraron tras la administración de infliximab.</p> <span class="elsevierStyleSectionTitle">Pacientes y método</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Se estudió a pacientes con psoriasis grave refractaria a otros tratamientos sistémicos, a los que se les administró infliximab (5 mg/kg) en las semanas 0, 2, 6, y posteriormente cada 8 semanas. Presentamos los resultados del Psoriasis Assessment and Severity Index (PASI) y de la Body Surface Assessment (BSA) en las semanas 6 y 30.</p> <span class="elsevierStyleSectionTitle">resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">El 90% de los pacientes experimentaron una mejoría en el PASI y la BSA respecto de los basales ya en la semana 6.El 63,6% de ellos alcanzó una mejoría del 75% en el PASI y el 72,7% una mejoría del 50% en la BSA. Esta mejoría se mantuvo hasta la semana 30 en un 54,5 y un 72,7%, respectivamente. El fármaco fue bien tolerado, sin reacciones adversas.</p> <span class="elsevierStyleSectionTitle">conclusiones</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El infliximab parece una Buena opción en el tratamiento de pacientes con psoriasis extensa y refractaria a tratamientos habituales.</p>" ] "en" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Background and objective</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor α and blocks the inflammatory response. The purpose of this study was to assess the effects of infliximab in patients with severe and refractory psoriasis</p> <span class="elsevierStyleSectionTitle">Patients and method</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Eleven patients with severe and refractory psoriasis were included in an open-label clinical trial. Patients received infliximab 5 mg/kg intravenously at weeks 0, 2, 6 and every 8 weeks. Psoriasis Assessment and Severity Index (PASI) and BSA (Body Surface Assessment) were used to monitor disease activity with each dose. Results at weeks 6 and 30 are shown.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">90% of patients improved their PASI and BSA basal scores early at sixth week, achieving 63.6% (PASI<span class="elsevierStyleInf">75</span>) and 72.7% (BSA<span class="elsevierStyleInf">50</span>). This improvement was mantained until the 30th week (54.5% and 72.7%, respectively). Infliximab was well tolerated and there was no significant adverse reaction.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Infliximab seems an effective therapy for severe and refractory psoriasis.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Referencias Bibliográficas" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomised trial." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "U. Chaudhari" 1 => "P. Romano" 2 => "L.D. Mulcahy" 3 => "L.T. Doodley" 4 => "D.G. Baker" 5 => "A.B. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2001" "volumen" => "357" "paginaInicial" => "1842" "paginaFinal" => "1847" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11410193" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis: immunopathology and immunomodulation." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.B. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatol Clin" "fecha" => "2001" "volumen" => "19" "paginaInicial" => "649" "paginaFinal" => "657" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11705352" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunopathogenesis of psoriasis." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.B. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1997" "volumen" => "133" "paginaInicial" => "781" "paginaFinal" => "782" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9197838" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factorαmonoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.B. Gottlieb" 1 => "S. Masud" 2 => "R. Ramamurthi" 3 => "A. Abdulghani" 4 => "P. Romano" 5 => "U. Chaudhari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2003.10" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "48" "paginaInicial" => "68" "paginaFinal" => "75" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12522373" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Schopf" 1 => "H. Aust" 2 => "J. Knop" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2002" "volumen" => "46" "paginaInicial" => "886" "paginaFinal" => "891" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12063486" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment with anti-tumor necrosis factor α (TNFα) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.J. Oh" 1 => "K.M. Das" 2 => "A.B. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2000" "volumen" => "42" "paginaInicial" => "829" "paginaFinal" => "830" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10775863" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The design of clinical trials in psoriasis: lessons for clinical practice." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S.R. Feldman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "49" "paginaInicial" => "62" "paginaFinal" => "65" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab for psoriasis." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.B. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2003.416" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "49" "paginaInicial" => "113" "paginaFinal" => "117" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12833020" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The immunology of psoriasis and biologic immunotherapy." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.L. Mehlis" 1 => "K.B. Gordon" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "49" "paginaInicial" => "44" "paginaFinal" => "50" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.B. Gotlieb" 1 => "U. Chaudhari" 2 => "L.D. Mulcahy" 3 => "S. Li" 4 => "L.T. Dooley" 5 => "D.G. Baker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2003.307" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "48" "paginaInicial" => "829" "paginaFinal" => "835" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12789171" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00257753/0000012300000017/v1_201307291635/S0025775304746345/v1_201307291635/es/main.assets" "Apartado" => array:4 [ "identificador" => "24087" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original breve" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00257753/0000012300000017/v1_201307291635/S0025775304746345/v1_201307291635/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775304746345?idApp=UINPBA00004N" ]
